Cargando…

Ixekizumab May Improve Renal Function in Psoriasis

Background: Psoriasis is a chronic dermatological condition characterized by lesions on extensor surfaces, hands, feet, and genital areas. Chronic renal failure is often associated with metabolic syndrome and inflammatory conditions, such as psoriasis. Case report: In this paper, we report a patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Amoruso, Giuseppe Fabrizio, Nisticò, Steven Paul, Iannone, Luigi, Russo, Emilio, Rago, Giuseppe, Patruno, Cataldo, Bennardo, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148436/
https://www.ncbi.nlm.nih.gov/pubmed/34066917
http://dx.doi.org/10.3390/healthcare9050543
_version_ 1783697837463175168
author Amoruso, Giuseppe Fabrizio
Nisticò, Steven Paul
Iannone, Luigi
Russo, Emilio
Rago, Giuseppe
Patruno, Cataldo
Bennardo, Luigi
author_facet Amoruso, Giuseppe Fabrizio
Nisticò, Steven Paul
Iannone, Luigi
Russo, Emilio
Rago, Giuseppe
Patruno, Cataldo
Bennardo, Luigi
author_sort Amoruso, Giuseppe Fabrizio
collection PubMed
description Background: Psoriasis is a chronic dermatological condition characterized by lesions on extensor surfaces, hands, feet, and genital areas. Chronic renal failure is often associated with metabolic syndrome and inflammatory conditions, such as psoriasis. Case report: In this paper, we report a patient with stage-three chronic renal failure that improved his renal condition after treatment with ixekizumab, an anti-IL17A drug used in the treatment of various cutaneous and rheumatological conditions. Conclusions: IL17A blockage may help to treat various autoimmune and inflammatory conditions, such as psoriasis, that may lead to renal impairment. Further investigation is necessary in order to prove the effectiveness of this drug in renal conditions.
format Online
Article
Text
id pubmed-8148436
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81484362021-05-26 Ixekizumab May Improve Renal Function in Psoriasis Amoruso, Giuseppe Fabrizio Nisticò, Steven Paul Iannone, Luigi Russo, Emilio Rago, Giuseppe Patruno, Cataldo Bennardo, Luigi Healthcare (Basel) Case Report Background: Psoriasis is a chronic dermatological condition characterized by lesions on extensor surfaces, hands, feet, and genital areas. Chronic renal failure is often associated with metabolic syndrome and inflammatory conditions, such as psoriasis. Case report: In this paper, we report a patient with stage-three chronic renal failure that improved his renal condition after treatment with ixekizumab, an anti-IL17A drug used in the treatment of various cutaneous and rheumatological conditions. Conclusions: IL17A blockage may help to treat various autoimmune and inflammatory conditions, such as psoriasis, that may lead to renal impairment. Further investigation is necessary in order to prove the effectiveness of this drug in renal conditions. MDPI 2021-05-07 /pmc/articles/PMC8148436/ /pubmed/34066917 http://dx.doi.org/10.3390/healthcare9050543 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Amoruso, Giuseppe Fabrizio
Nisticò, Steven Paul
Iannone, Luigi
Russo, Emilio
Rago, Giuseppe
Patruno, Cataldo
Bennardo, Luigi
Ixekizumab May Improve Renal Function in Psoriasis
title Ixekizumab May Improve Renal Function in Psoriasis
title_full Ixekizumab May Improve Renal Function in Psoriasis
title_fullStr Ixekizumab May Improve Renal Function in Psoriasis
title_full_unstemmed Ixekizumab May Improve Renal Function in Psoriasis
title_short Ixekizumab May Improve Renal Function in Psoriasis
title_sort ixekizumab may improve renal function in psoriasis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148436/
https://www.ncbi.nlm.nih.gov/pubmed/34066917
http://dx.doi.org/10.3390/healthcare9050543
work_keys_str_mv AT amorusogiuseppefabrizio ixekizumabmayimproverenalfunctioninpsoriasis
AT nisticostevenpaul ixekizumabmayimproverenalfunctioninpsoriasis
AT iannoneluigi ixekizumabmayimproverenalfunctioninpsoriasis
AT russoemilio ixekizumabmayimproverenalfunctioninpsoriasis
AT ragogiuseppe ixekizumabmayimproverenalfunctioninpsoriasis
AT patrunocataldo ixekizumabmayimproverenalfunctioninpsoriasis
AT bennardoluigi ixekizumabmayimproverenalfunctioninpsoriasis